ReachMD Logo
GLC Logo
Background

MASLD/MASH Learning Center

Advancing Care in Metabolic-Associated Steatohepatitis

MASLD/MASH Educational Content

Your Comprehensive Hub for Excellence in Education on MASLD/MASH

Through expert interviews, case discussions, expert panels, and patient perspectives, leading global experts deliver the latest evidence-based guidance and real-world outcomes for practicing clinicians. Join our growing community of endocrinology, obesity medicine, primary care, gastroenterology and hepatology providers by engaging with the educational content in this learning center and sharing it with your colleagues in your healthcare team.

Together, we can advance the standard of MASLD/MASH care worldwide!

0.0M

It is estimated that by 2030 and 2050, 101.2 million and 121.9 million adults in the US will have MASLD.1

0.0M

It is estimated that in 2020, 14.9 million adults in the US had MASH, which is expected to increase to 23.2 million by 2050.1

Most common

MASLD is the most common cause of chronic liver disease and is projected to become the leading indication for liver transplant in the US.1

Leading causes

Cardiovascular disease is the leading cause of morbidity and mortality in patients with MASLD.2

References: 1. PMC11742522; 2. ScienceDirect Article

Educational Activities

Treating MASH With Compensated Cirrhosis: A Serious Unmet Need
CME/CE
View Activity

Treating MASH With Compensated Cirrhosis: A Serious Unmet Need

0.25 Credits
Treating MASH With Compensated Cirrhosis: A Serious Unmet Need
CME/CE
View Activity

Treating MASH With Compensated Cirrhosis: A Serious Unmet Need

0.25 Credits
The Changing Paradigm of Treating MASLD/MASH: At the Crossroads of Hepato-Cardiometabolic Care – Chair's Perspective
CME/CE
View Activity

The Changing Paradigm of Treating MASLD/MASH: At the Crossroads of Hepato-Cardiometabolic Care – Chair's Perspective

0.25 Credits
Stemming the Tide on MASLD/MASH: It Starts on the Frontlines in Endocrinology and Primary Care Clinics
CME/CE
View Activity

Stemming the Tide on MASLD/MASH: It Starts on the Frontlines in Endocrinology and Primary Care Clinics

1.00 Credits
Chairperson's Perspective: Treating At-Risk MASH: What Are You Waiting For?
CME/CE
View Activity

Chairperson's Perspective: Treating At-Risk MASH: What Are You Waiting For?

0.25 Credits
Advances in the Treatment and Management of MASH: More Options, More Decisions
CME/CE
View Activity

Advances in the Treatment and Management of MASH: More Options, More Decisions

1.50 Credits
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair's Perspective
CME/CE
View Activity

Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair's Perspective

0.25 Credits

Resource Center

Discover a curated collection of foundational, practical, cutting-edge and real-world educational resources at your fingertips.

Faculty

Meet our distinguished team of experts dedicated to advancing MASLD/MASH care and education worldwide.

Naim Alkhouri, MD, FAASLD, DABOM

Naim Alkhouri, MD, FAASLD, DABOM

Mazen Noureddin, MD, MHSc

Mazen Noureddin, MD, MHSc

Meena B. Bansal, MD, FAASLD

Meena B. Bansal, MD, FAASLD

Fernando Bril, MD

Fernando Bril, MD

Nicholas Pennings, DO, DABOM, MFOMA, FACOFP, FAAFP

Nicholas Pennings, DO, DABOM, MFOMA, FACOFP, FAAFP

Jennifer R. Berg

Jennifer R. Berg

Mary E. Rinella, MD, FAASLD

Mary E. Rinella, MD, FAASLD

Naga Chalasani, MD, FAASLD

Naga Chalasani, MD, FAASLD